Filing summary
Entity discrepancy: The supplied filing is Sigma Labs, Inc.’s Form 10-Q, not a Nexttrip, Inc. filing. It covers the quarter ended March 31, 2014 and was signed May 15, 2014.
Business context and reporting period
Sigma Labs develops manufacturing and materials technologies, with a current focus on its In-Process Quality Assurance (IPQA) products for metal additive manufacturing. It also earns revenue from engineering consulting. The financial statements are unaudited and consolidated.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 / prior date |
|---|---|---|
| Revenue | $114,829 | $164,264 |
| Cost of service revenue | $55,889 | $86,930 |
| Gross profit / margin | $58,940 / 51.3% | $77,334 / 47.1% |
| General and administrative expense | $249,543 | $135,551 |
| Payroll expense | $251,945 | $88,409 |
| Net loss | $(466,906) | $(196,616) |
| Operating cash flow | $(300,504) | $44,410 |
| Cash | $4,010,281 | $992,448 at Dec. 31, 2013 |
| Working capital | $4,059,718 | $1,180,973 at Dec. 31, 2013 |
| Total liabilities | $97,634 | $141,161 at Dec. 31, 2013 |
The filing reports no income tax expense. No debt balance is presented; the company stated it had no credit lines or credit facilities. Cash increased by $3.02 million, mainly from $3.5 million of stock-sale proceeds, less $181,663 of offering costs and operating cash use. The company reported no investing cash flows.
Material changes versus comparable period
- Revenue fell about 30%; gross profit declined about 24%, though gross margin rose to 51.3% from 47.1%.
- Net loss increased to $466,906 from $196,616, primarily due to lower revenue and higher wages and professional fees.
- Payroll expense increased by about $164,000, principally reflecting a $175,000 performance bonus paid to the CEO. G&A rose about $114,000, attributed principally to increased R&D and consulting services.
- Operating cash flow shifted from $44,410 provided to $300,504 used.
- In January 2014, the company sold 43.75 million shares for $3.5 million gross proceeds (about $3.30 million net). Common shares outstanding rose from 556.8 million at year-end to 600.8 million at quarter-end. The offering also included warrants for 14.26 million shares; a consultant received warrants for another 2.19 million shares.
Outlook, risks, and unusual items
- Management expected continued IPQA development to support commercialization in the remainder of 2014 and 2015. The filing provides no quantified revenue or earnings guidance.
- As of May 15, management expected three active consulting contracts to generate up to approximately $240,000 in revenue during the rest of 2014. It also stated it believed available funds and expected receipts could cover operating and administrative expenses through 2015.
- The company cautioned that continued funding depends on consulting revenue, technology commercialization, and/or additional securities sales or borrowing. It warned that unavailable or unacceptable financing could require it to curtail or cease operations.
- The financial statements include a going-concern note: the company has sustained losses since inception, and profitable operations and additional capital are not assured.
- Fixed-price consulting contracts carry cost-estimation and execution risks. Management decided to discontinue servicing Sumner’s contract and planned to dissolve the Sumner subsidiary during 2014.
- In April 2014, the company issued 850,000 shares to employees and a director, valued at $115,600. The filing states no other subsequent events requiring disclosure.
- Management said disclosure controls were effective at a reasonable assurance level; it reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing identifies Sigma Labs, Inc., despite the request metadata naming Nexttrip, Inc.
- Check progress toward IPQA commercialization and whether anticipated consulting-contract revenue is realized.
- Monitor cash burn, funding needs, and any subsequent equity issuance or borrowing; review dilution from outstanding warrants and shares.
- Assess the sustainability of operating expenses, including executive compensation and R&D spending, relative to revenue.
- Review the company’s latest going-concern disclosures and any developments in its Sumner subsidiary or fixed-price contracts.